Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0038187 (
starvation
)
24,951
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Depletion of yeast/fly Ataxin-2 rescues TDP-43 overexpression toxicity. In mouse models of Amyotrophic Lateral Sclerosis via TDP-43 overexpression, depletion of its ortholog ATXN2 mitigated motor neuron degeneration and extended lifespan from 25 days to >300 days. There is another ortholog in mammals, named
ATXN2L
(Ataxin-2-like), which is almost uncharacterized but also functions in RNA surveillance at stress granules. We generated mice with Crispr/Cas9-mediated deletion of
Atxn2l
exons 5-8, studying homozygotes prenatally and heterozygotes during aging. Our novel findings indicate that
ATXN2L
absence triggers mid-gestational embryonic lethality, affecting female animals more strongly. Weight and development stages of homozygous mutants were reduced. Placenta phenotypes were not apparent, but brain histology showed lamination defects and apoptosis. Aged heterozygotes showed no locomotor deficits or weight loss over 12 months. Null mutants in vivo displayed compensatory efforts to maximize
Atxn2l
expression, which were prevented upon nutrient abundance in vitro. Mouse embryonal fibroblast cells revealed more multinucleated giant cells upon
ATXN2L
deficiency. In addition, in human neural cells, transcript levels of
ATXN2L
were induced upon
starvation
and glucose and amino acids exposure, but this induction was partially prevented by serum or low cholesterol administration. Neither
ATXN2L
depletion triggered dysregulation of ATXN2, nor a converse effect was observed. Overall, this essential role of
ATXN2L
for embryogenesis raises questions about its role in neurodegenerative diseases and neuroprotective therapies.
...
PMID:Mid-Gestation lethality of
Atxn2l
-Ablated Mice. 3269 85